Sanofi (SNY) Posts Ligter EPS for Q4; Sees FY16 Business EPS to be 'Stable'

Sanofi (NYSE: SNY) reported Q4 EPS of EUR1.31, versus EUR1.39 reported last year. Revenue for the quarter came in at EUR9.27 billion, versus EUR9.07 billion reported last year.

Executing on 2020 strategic roadmap

• Key milestone in reshaping the portfolio with announcement of exclusive negotiations on business swap
• Significant R&D alliances in oncology and diabetes
• Praluent^® launch progressing with significant U.S. market access for 2016
• Toujeo^® available globally in over 20 countries, reaching sales of €98 million in Q4 2015

Recent achievements in advancing Sanofi's R&D pipeline of innovative medicines

• Dengvaxia^®, the world's first dengue vaccine, approved in Mexico, Brazil, El Salvador and the Philippines
• Biologics License Application for sarilumab accepted for review by the FDA
• FDA submission for priority review of once-daily combination of insulin glargine and lixisenatide

Sales growth in Pharmaceuticals, Vaccines and Animal Health in 2015

• Aggregate Group sales⁽²⁾ up 2.2%⁽³⁾ (+9.7% at 2015 exchange rates) to €37,057 million
• Genzyme continues to be a key driver with sales up 29.5% with strong momentum in multiple sclerosis
• Vaccines sales were up 7.3% benefiting from double-digit growth in Emerging Markets⁽⁴⁾
• Diabetes sales decreased 6.8% in line with October guidance, reflecting lower U.S. sales of Lantus^®
• Animal Health demonstrated strong performance with sales up 10.8% driven by NexGard^®
• Emerging Markets Aggregate sales increased 7.8%, driven by strong growth in China, up 19.5%

Solid financial results in 2015 while making significant investments in new product launches

• Business EPS was €5.64, up 8.5% on a reported basis and stable at CER
• Free Cash Flow up 12.2% to €8,132 million resulting in net debt of €7,254 million
• Board proposes dividend of €2.93, the 22^nd consecutive year of dividend growth

2016 financial guidance

• Sanofi expects 2016 Business EPS⁽¹⁾ to be broadly stable⁽⁵⁾ at CER, barring unforeseen major adverse events

For earnings history and earnings-related data on Sanofi (SNY) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Accenture downgraded by TD Cowen on AI concerns
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits